Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab <i>versus</i> bevacizumab alone in women with newly diagnosed advanced ovarian cancer.

Hettle, Robert; McCrea, Charles; Lee, Chee Khoon; Davidson, Richard

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer.

Hettle, Robert; McCrea, Charles; Lee, Chee Khoon; Davidson, Richard.

Afiliação

Hettle R; Health Economics and Payer Evidence, AstraZeneca, Academy House, 136 Hills Road, Cambridge, Cambridgeshire CB2 8PA, UK.
McCrea C; Health Economics and Payer Evidence, AstraZeneca, Cambridge, UK.
Lee CK; Cancer Care Centre, St George Hospital, Sydney, Australia.
Davidson R; Global Medical Affairs, AstraZeneca, Cambridge, UK.

Ther Adv Med Oncol ; 13: 17588359211049639, 2021.

Article em En | MEDLINE | ID: mdl-34616492

Palavras-chave

bevacizumab; homologous recombination deficiency; indirect treatment comparison; niraparib; olaparib; ovarian cancer

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_ovary_cancer Tipo de estudo: Clinical_trials / Diagnostic_studies Idioma: En Revista: Ther Adv Med Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google